The AIUR Trial: Surgical Gloves to Prevent Peripheral Neuropathy

Inclusion Criteria: * Age greater or equal to 19 years, under 70 years old * Stage II-III breast cancer * No distant metastasis * Patient scheduled to be receiving adjuvant or neoadjuvant paclitaxel for at least 12 weeks * Signed informed consent * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥60%) Exclusion Criteria: * Recurred breast cancer * Patients who have previously received treatment that could cause neuropathy; taxane or platinum-based chemotherapy, antitubulins, proteasome inhibitors * Known history of neuropathy * Chronic kidney disease * Raynaud's phenomenon * Peripheral vascular disease; peripheral arterial ischemia * Cold intolerance * Allergy in natural rubber latex or surgical gloves * Patients who have dermatitis, wound, or musculoskeletal problems in hand at enrollment * Current use medications which may mitigate chemotherapy-induced peripheral neuropathy; duloxetine, gabapentin/pregabalin, Baclofen-amitriptyline-ketamine (BAK; topical amitriptyline, ketamine, ±baclofen), oral cannabinoids, tricyclic antidepressants, ganglioside-monosialic acid